DE3851776D1 - Verwendung von IGF-II zur Behandlung von Knochenkrankheiten. - Google Patents

Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.

Info

Publication number
DE3851776D1
DE3851776D1 DE3851776T DE3851776T DE3851776D1 DE 3851776 D1 DE3851776 D1 DE 3851776D1 DE 3851776 T DE3851776 T DE 3851776T DE 3851776 T DE3851776 T DE 3851776T DE 3851776 D1 DE3851776 D1 DE 3851776D1
Authority
DE
Germany
Prior art keywords
igf
treatment
bone diseases
bone
osteoporosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3851776T
Other languages
English (en)
Other versions
DE3851776T2 (de
Inventor
David J Baylink David Baylink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878710676A external-priority patent/GB8710676D0/en
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of DE3851776D1 publication Critical patent/DE3851776D1/de
Application granted granted Critical
Publication of DE3851776T2 publication Critical patent/DE3851776T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE3851776T 1987-04-28 1988-04-28 Verwendung von IGF-II zur Behandlung von Knochenkrankheiten. Expired - Fee Related DE3851776T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4362887A 1987-04-28 1987-04-28
GB878710676A GB8710676D0 (en) 1987-05-06 1987-05-06 Pharmacologically active peptides

Publications (2)

Publication Number Publication Date
DE3851776D1 true DE3851776D1 (de) 1994-11-17
DE3851776T2 DE3851776T2 (de) 1995-05-04

Family

ID=26292207

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3851776T Expired - Fee Related DE3851776T2 (de) 1987-04-28 1988-04-28 Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.

Country Status (4)

Country Link
EP (1) EP0289314B1 (de)
AT (1) ATE112684T1 (de)
DE (1) DE3851776T2 (de)
ES (1) ES2063033T3 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027903A (en) * 1987-11-06 2000-02-22 Washington Research Foundation Kit for detecting analyte indicative of type I collagen resorption in vivo
US4973666A (en) * 1987-11-06 1990-11-27 Washington Research Foundation Peptide fragments containing HP and LP cross-links
US5300434A (en) * 1987-11-06 1994-04-05 Washington Research Foundation Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide
US5962639A (en) * 1987-11-06 1999-10-05 Washington Research Foundation Synthetic peptides corresponding to telopeptide sequences of cross-linked type I collagen metabolites
US6153732A (en) * 1987-11-06 2000-11-28 Washington Research Foundation Kit for detecting analyte indicative of type II collagen resorption in vivo
US5320970A (en) * 1987-11-06 1994-06-14 Washington Research Foundation Detection of collagen degradation in vivo
US5702909A (en) * 1987-11-06 1997-12-30 Washington Research Foundation Methods of detecting collagen type II degradation in vivo
JPH03151877A (ja) * 1989-06-02 1991-06-28 Chiron Corp 骨カルシウム沈着因子
US6723699B1 (en) 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6693076B1 (en) 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
CA2020729A1 (en) * 1989-07-19 1991-01-20 Michael C. Kiefer Bone morphogenetic protein
GB8927008D0 (en) * 1989-11-29 1990-01-17 Ciba Geigy Novel process for the production of unfused protein in e.coli
NZ236618A (en) 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5071655A (en) * 1990-01-12 1991-12-10 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
DK27390D0 (da) * 1990-02-02 1990-02-02 Troels Torp Andreassen Fremgangsmaade og apparat til administration af biologisk aktive stoffer
WO1992018154A1 (en) * 1991-04-19 1992-10-29 Boehringer Mannheim Gmbh Human bone derived insulin like growth factor binding protein
WO1993003152A1 (en) * 1991-07-29 1993-02-18 British Bio-Technology Limited Igf-ii analogues
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
TW267102B (de) 1992-03-13 1996-01-01 Ciba Geigy
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
US6916790B2 (en) 1997-05-05 2005-07-12 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
DE69835878T2 (de) * 1997-05-05 2007-04-26 Mayo Foundation For Medical Education And Research, Rochester IGFIIE/ IGFBP2 Komplex
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
DE60232880D1 (de) 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287219A (en) * 1963-08-05 1966-11-22 Charles J Nemanick Method of healing bone fractures
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
DE3343253A1 (de) * 1983-08-11 1985-02-21 Neill Bailey San Antonio Tex. Walsdorf Fluorid-tablette mit verzoegerter wirkstoff-freigabe und verfahren zu ihrer herstellung
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing

Also Published As

Publication number Publication date
EP0289314A3 (en) 1990-11-22
ES2063033T3 (es) 1995-01-01
EP0289314A2 (de) 1988-11-02
ATE112684T1 (de) 1994-10-15
EP0289314B1 (de) 1994-10-12
DE3851776T2 (de) 1995-05-04

Similar Documents

Publication Publication Date Title
DE3851776T2 (de) Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69200675T2 (de) Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen.
DK0670729T3 (da) Anvendelse af insulin-lignende vækstfaktorer og analoger til behandling af retinale nervesygdomme
ATE157251T1 (de) Verwendung von inositoltriphosphat zur behandlung von entzündungen
ATE151293T1 (de) Igf-i zur verbesserung der neuronale lage
DK2907522T1 (da) Fremgangsmåde til øgning af knoglesejhed og -stivhed og nedsættelse af frakturer
GR3007202T3 (de)
ATE308336T1 (de) Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
BR0317888A (pt) Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
BR9910329A (pt) Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
DE3850154T2 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
DE68924006D1 (de) Pharmazeutische Zusammensetzungen mit Eierschalenbestandteilen und ihre Herstellung und Verwendung.
DE69501359T2 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
ATE183651T1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
HU9301726D0 (en) Compounds and preparatives hindering resorption of bones
EA200301041A1 (ru) Стимуляция остеогенеза с использованием гибридных белков лиганда для rank
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
EP0373771A3 (de) Neue pharmazeutische Anwendungen von Cystatinen
DE69621786T2 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
AP9901474A0 (en) Pharmaceutical composition for treating viral diseases.
SE8403659D0 (sv) Synergistic pharmaceutical composition
DE3687233T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ROCHE DIAGNOSTICS GMBH, 68305 MANNHEIM, DE

8339 Ceased/non-payment of the annual fee